Effect of cisplatin on rat placenta development

Area of Science:

• Reproductive toxicology
• Developmental biology
• Histopathology

Background:

• Cisplatin is a widely used chemotherapy agent with known teratogenic effects.
• Placental development is crucial for fetal growth and survival.
• Understanding cisplatin's impact on placental structure is vital for risk assessment.

Purpose of the Study:

• To investigate the sequential histopathological changes in rat placentas following cisplatin administration.
• To determine the effects of cisplatin on different placental zones and their development.
• To correlate placental abnormalities with fetal outcomes.

Main Methods:

• Intraperitoneal administration of cisplatin (2 mg/kg/day) to pregnant rats during specific gestational days (GDs 11-12 or 13-14).
• Placental sampling at various time points (GDs 13, 15, 17, 21).
• Macroscopic and histopathological examination, including assessment of apoptotic cells and cell proliferation markers (Phospho-Histone H3).

Main Results:

• Cisplatin treatment led to reduced placental weight and size, evident from GD 15 onwards.
• Histopathological analysis revealed increased apoptosis and hypoplasia in the labyrinth and basal zones of the placenta.
• Decreased cell proliferation (Phospho-Histone H3) and impaired glycogen cell-island development were observed, leading to metrial gland hypoplasia.
• Fetal mortality increased significantly, and fetal weights were reduced in the earlier treatment group.

Conclusions:

• Cisplatin administration induces placental growth arrest in specific zones, resulting in smaller placentas.
• Metrial gland hypoplasia appears secondary to impaired basal zone development and glycogen cell-island formation.
• These placental changes likely contribute to the observed fetal growth restriction and increased mortality.